Abbott Q3 2026 Earnings: Nutrition Spin-Off Overshadows Solid Underlying Growth

Abbott reported third-quarter sales of $13.013B, up 14.5% on a reported basis and 7.0% on a comparable basis, while adjusted EPS rose 9.2% to $1.42. The underlying operating picture remained solid across medical devices, diagnostics and established pharmaceuticals, but GAAP earnings fell sharply as acquisition-related amortization, legal settlements and other specified charges increased.

The defining development was Abbott’s plan to separate its Nutrition business into an independent public company by the end of 2027. The transaction would leave Abbott more concentrated in medical devices, diagnostics and established pharmaceuticals, while creating a standalone nutrition company with approximately $8.5B in annual sales.

Earnings Snapshot

The Bigger Story

Abbott’s planned Nutrition separation is a substantial portfolio move rather than a response to a weak operating quarter. Management said the business has evolved from a primarily healthcare-professional-driven market toward one influenced more heavily by consumer preferences, wellness trends and retail execution. It concluded that Nutrition needs a more independent commercial and investment model than Abbott’s technology-oriented healthcare businesses.

The planned tax-free distribution is expected to be completed by the end of next year, subject to approvals. Abbott shareholders are expected to receive shares in both companies, although the distribution ratio has not been determined.

For the remaining Abbott portfolio, management expects the absence of Nutrition to increase sales growth by 50 to 100 basis points, gross margin by more than 200 basis points, and operating margin by approximately 100 basis points. Those are expected post-separation portfolio characteristics, not current reported results.

The transaction also introduces execution and capital-allocation questions. The new Nutrition company is expected to raise debt, with a portion of the proceeds distributed to Abbott, though neither the debt amount nor the distribution amount has been set. Management expects both entities to retain investment-grade credit ratings and said the combined dividends of the two companies would equal Abbott’s dividend at the time of the separation.

Revenue and Operating Performance

Reported sales growth was amplified by Abbott’s March acquisition of Exact Sciences. Diagnostics revenue rose 46.7% to $3.305B, but comparable growth was 6.4% after including historical Exact Sciences revenue in both periods. The distinction matters: the acquisition materially increased the reported revenue base, while the legacy diagnostics business delivered mid-single-digit underlying growth.

Core Laboratory Diagnostics grew 5.4% on a comparable basis, with growth across the U.S., Europe, Japan and Latin America. Management said instrument-based testing data continued to indicate stable healthcare testing demand.

Cancer Diagnostics grew 13.8% on a comparable basis, driven by Cologuard, precision oncology and international operations. Management said a cybersecurity event during the quarter interrupted connectivity at some health systems for roughly seven to 10 days, reducing cancer diagnostics growth by about one percentage point. It characterized the disruption as temporary, noting volumes rebounded after systems resumed connectivity.

Medical Devices remained Abbott’s largest business at $5.826B of quarterly revenue and delivered 7.8% comparable growth. Electrophysiology grew 15.5%, while Rhythm Management increased 10.0%, supported by adoption of the AVEIR leadless pacemaker platform. Management said electrophysiology growth excluding left atrial appendage, or LAA, products was in the mid- to high-teens, with U.S. growth above 20%.

Diabetes Care grew 6.7% on a comparable basis, including 7.7% growth in continuous glucose monitor sales. That growth is now more important to assess against management’s updated outlook: Abbott expects Diabetes Care growth to slow to the low- to mid-single-digit range for the next several quarters as international pricing pressure rises and U.S. penetration of non-intensive Type 2 diabetes patients remains constrained without further reimbursement expansion.

Nutrition grew 4.9% on a comparable basis, including 8.7% growth in Pediatric Nutrition. U.S. pediatric sales rose 11.0%, aided by WIC contract wins secured earlier in the year. Adult Nutrition was less robust, rising 1.8% globally, although U.S. adult sales increased 3.5%. Nutrition sales also improved sequentially by $118M from the second quarter, suggesting the business entered the planned separation from a more stable operating position than its nine-month results imply. For the first nine months, comparable Nutrition sales remained down 2.1%.

Established Pharmaceuticals grew 8.4% on a comparable basis. Key Emerging Markets expanded 10.9%, led by double-digit growth in India and selected Latin American and Asia-Pacific markets. This business continues to provide a geographically diversified source of growth, though it will remain exposed to currency movements and local-market pricing dynamics.

Profitability and Margins

Adjusted earnings growth was stronger than the GAAP result suggests. Adjusted EPS increased 9.2% to $1.42, while adjusted operating margin expanded 40 basis points to 23.4%. Adjusted gross margin improved 140 basis points to 57.2%, which management attributed to favorable business mix, Exact Sciences and ongoing margin initiatives.

GAAP diluted EPS, however, declined to $0.53 from $0.94. Operating earnings fell 34.0% to $1.358B, and net earnings declined 44.1% to $920M.

The gap between GAAP and adjusted results widened materially. Abbott excluded $1.557B after tax, or $0.89 per share, in specified items during the quarter, compared with $634M, or $0.36 per share, a year earlier. The largest components were $841M of intangible amortization and approximately $670M of legal settlements. The latter primarily related to agreements to resolve the Gill case and necrotizing enterocolitis, or NEC, claims asserted for approximately 2,000 additional infants.

Higher interest expense also weighed on reported profit, increasing to $297M from $44M a year earlier. Investors should therefore view the adjusted margin gains alongside a significantly larger level of excluded costs and a higher financing burden.

Demand, Customers and Pricing

Demand trends were broadly healthy in core laboratory diagnostics, cardiovascular devices and established pharmaceuticals. The more important change came in diabetes, where Abbott acknowledged a more challenging near-term pricing and reimbursement backdrop.

Management said international continuous glucose monitor pricing is under pressure as competition expands. Abbott plans selective pricing adjustments to defend its market position and secure longer-term contracts, potentially including provisions tied to patient-population expansion. Management expects manufacturing and cost-of-goods initiatives to offset the resulting margin pressure.

In the U.S., management cited the lack of a major reimbursement expansion for Type 2 diabetes patients not using insulin as a limitation on market penetration. Abbott does not currently include a potential Centers for Medicare & Medicaid Services reimbursement expansion in its near-term outlook. If such coverage is adopted, management believes it could materially accelerate CGM demand, but timing remains uncertain.

In electrophysiology, the near-term issue is LAA. Management said LAA market dynamics and a slowdown in U.S. orders following the CE Mark approval of Amulet 360 reduced its expected fourth-quarter electrophysiology growth rate. Some customers appear to be waiting for the new device before placing orders. Abbott expects the headwind to persist through the fourth quarter, before product launches and broader adoption help restore momentum.

What Is Abbott’s Guidance for Q4 and Full-Year 2026?

Abbott projects full-year 2026 comparable sales growth of approximately 6.0%.

The company tightened full-year adjusted diluted EPS guidance to $5.50 to $5.55, reaffirming the midpoint of its prior range. Abbott also projects fourth-quarter adjusted diluted EPS of $1.62 to $1.67.

Management expects foreign exchange to reduce fourth-quarter sales growth by approximately 1% at current rates.

Management indicated that the 6% full-year sales outlook implies comparable growth of just over 8% in the fourth quarter. The anticipated acceleration is despite lower expected contributions from electrophysiology and diabetes relative to prior expectations.

For 2027, management did not provide formal guidance. It said it expects total company sales growth to accelerate, but plans to take a more conservative approach to its initial revenue outlook after a year in which sales growth fell short of prior expectations. Management expects continued gross-margin expansion, EPS growth, R&D investment and dividend growth.

Balance Sheet, Cash Flow and Capital

Abbott did not disclose quarterly cash flow or balance-sheet figures in its earnings release. Capital allocation was nevertheless central to the Nutrition separation announcement.

The company expects the new Nutrition entity to raise debt and distribute a portion of the proceeds to Abbott. Management said the capital structures will be designed to support each company’s growth plans, capital-allocation priorities and investment-grade credit ratings.

Abbott also said its final major debt repayment related to the St. Jude Medical and Alere acquisitions is expected this year. Management expects net debt to EBITDA of around 2 times and described future M&A capacity as sufficient, though it suggested the near-term focus would be on smaller tuck-in acquisitions while Exact Sciences integration continues.

The quarterly dividend of $0.63 per share is payable November 16 to shareholders of record on October 15. Abbott has increased its dividend for 54 consecutive years.

What Investors Should Watch

1. Nutrition Separation Details

The planned spin-off changes Abbott’s future revenue mix, margin profile and capital structure. Investors should watch for the debt allocation, share-distribution ratio, separation costs, standalone financial disclosures and the eventual handling of Nutrition-related legal liabilities.

2. Diabetes Growth and International Pricing

CGM sales still grew 7.7% on a comparable basis in the quarter, but management now anticipates low- to mid-single-digit growth over the next several quarters. Evidence that pricing actions protect volume and market share without a meaningful margin hit will be important.

3. Electrophysiology Product Conversion

Abbott expects Volt, TactiFlex Duo and eventually Amulet 360 to support renewed electrophysiology growth. The immediate test is whether the LAA order slowdown clears after the new product launches and whether the ablation portfolio continues taking share.

4. Exact Sciences Integration and Cancer Diagnostics Growth

Cancer Diagnostics grew 13.8% on a comparable basis, despite the cybersecurity disruption. Investors should monitor Cologuard user growth, care-gap program timing, the ramp of the SimpleScreen blood-based test and continued margin improvement in the acquired business.

5. GAAP Cost Burden and Legal Settlements

Adjusted EPS growth remains intact, but GAAP earnings were heavily affected by $1.557B of specified charges. Future legal costs, acquisition-related expenses, amortization and separation costs will determine how quickly reported profitability converges with adjusted results.

AlgovestIQ Takeaway

Abbott’s third quarter showed continued underlying growth across the portfolio, led by medical devices, cancer diagnostics and emerging-market pharmaceuticals. Comparable sales growth of 7.0% and adjusted EPS growth of 9.2% support management’s view that operating momentum improved from the first half.

The Nutrition separation is the more consequential development. It should create a faster-growing and higher-margin remaining Abbott, based on management’s expectations, while giving Nutrition a structure designed for a consumer-oriented market. But the benefits will not be realized until a complex separation is completed, capital structures are established and each company proves it can execute independently.

The most significant near-term operating concern is the moderation in Diabetes Care. Abbott’s leading CGM franchise is still expanding, but international pricing concessions and delayed reimbursement expansion for non-intensive Type 2 diabetes patients have reduced management’s near-term growth outlook. Electrophysiology also faces a temporary LAA-related headwind, although its new ablation products offer a plausible path to reacceleration.

The central investment question is whether Abbott can translate a deep product pipeline and Exact Sciences integration into sustained growth while navigating pricing pressure, legal costs and the Nutrition separation. Stronger evidence would include a recovery in diabetes growth, successful conversion of LAA demand to Amulet 360, continued cancer-diagnostics margin expansion and a well-capitalized spin structure. Weaker evidence would be continued revenue-guide pressure, more substantial CGM price erosion or escalating excluded legal and separation costs.